Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)

Conclusion: The benefit of BUD treatment in reducing risk of CID is dependent on EOS. EOS may be used to identify COPD patients suitable for ICS treatment and studies evaluating ICS treatment effect.

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Bafadhel, M., Sing, D., Jenkins, C., Peterson, S., Bengtsson, T., Fageras, M. Tags: Monitoring Airway Disease Source Type: research